^
Association details:
Biomarker:EGFR L747P
Cancer:Non Small Cell Lung Cancer
Drug:gefitinib (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma

Excerpt:
Soon afterwards the patient requested EGFR genetic analysis of the cancerous tissue, and sequencing revealed the presence of the rare mutation L747P (2239-2240 TT>CC), but no other mutations were found (Figure 3). Oral gefitinib was firstly administered at a daily dose of 250 mg based on the patient’s condition, but a poor response was observed,...